Combination of androgen deprivation therapy and radiotherapy for localized prostate cancer in the contemporary era

Rolando M. D'Angelillo; Pierfrancesco Franco; Berardino De Bari; Alba Fiorentino; Stefano Arcangeli; Filippo Alongi

doi:10.1016/j.critrevonc.2014.10.003

Combination of androgen deprivation therapy and radiotherapy for localized prostate cancer in the contemporary era

Rolando M. D'Angelillo, Pierfrancesco Franco, Berardino De Bari, Alba Fiorentino, Stefano Arcangeli, Filippo Alongi

Risultato della ricerca: Contributo su rivista › Articolo di review › peer review

Abstract

Currently, androgen deprivation therapy (ADT) has a well-defined role when administered together with radiotherapy (RT): neo-adjuvant and concurrent combination for intermediate risk-disease and adjuvant therapy for high risk disease. Evidence of this association was generated by randomized trials designed and led approximately 30 years ago; thus the question which arises is how relevant and portable are these data in our current clinical practice?In the present review, we examine the pitfalls of these published randomized controlled trials, their relevance to present daily clinics, where high-dose external beam RT or brachytherapy is applied, as well as the adoption of ADT in patients with concomitant cardiovascular disorders.

Lingua originale	Inglese
pagine (da-a)	136-148
Numero di pagine	13
Rivista	Critical Reviews in Oncology/Hematology
Volume	93
Numero di pubblicazione	2
DOI	https://doi.org/10.1016/j.critrevonc.2014.10.003
Stato di pubblicazione	Pubblicato - 1 feb 2015
Pubblicato esternamente	Sì

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

Accesso al documento

10.1016/j.critrevonc.2014.10.003

Altri file e collegamenti

Link to publication in Scopus

Cita questo

@article{ae27ce5c05944fefaf3b16e075599d05,

title = "Combination of androgen deprivation therapy and radiotherapy for localized prostate cancer in the contemporary era",

abstract = "Currently, androgen deprivation therapy (ADT) has a well-defined role when administered together with radiotherapy (RT): neo-adjuvant and concurrent combination for intermediate risk-disease and adjuvant therapy for high risk disease. Evidence of this association was generated by randomized trials designed and led approximately 30 years ago; thus the question which arises is how relevant and portable are these data in our current clinical practice?In the present review, we examine the pitfalls of these published randomized controlled trials, their relevance to present daily clinics, where high-dose external beam RT or brachytherapy is applied, as well as the adoption of ADT in patients with concomitant cardiovascular disorders.",

keywords = "Androgen deprivation therapy, Brachytherapy, Prostate cancer, Radiotherapy",

author = "D'Angelillo, \{Rolando M.\} and Pierfrancesco Franco and \{De Bari\}, Berardino and Alba Fiorentino and Stefano Arcangeli and Filippo Alongi",

note = "Publisher Copyright: {\textcopyright} 2014 Elsevier Ireland Ltd.",

year = "2015",

month = feb,

day = "1",

doi = "10.1016/j.critrevonc.2014.10.003",

language = "English",

volume = "93",

pages = "136--148",

journal = "Critical Reviews in Oncology/Hematology",

issn = "1040-8428",

publisher = "Elsevier Ireland Ltd",

number = "2",

}

TY - JOUR

T1 - Combination of androgen deprivation therapy and radiotherapy for localized prostate cancer in the contemporary era

AU - D'Angelillo, Rolando M.

AU - Franco, Pierfrancesco

AU - De Bari, Berardino

AU - Fiorentino, Alba

AU - Arcangeli, Stefano

AU - Alongi, Filippo

PY - 2015/2/1

Y1 - 2015/2/1

N2 - Currently, androgen deprivation therapy (ADT) has a well-defined role when administered together with radiotherapy (RT): neo-adjuvant and concurrent combination for intermediate risk-disease and adjuvant therapy for high risk disease. Evidence of this association was generated by randomized trials designed and led approximately 30 years ago; thus the question which arises is how relevant and portable are these data in our current clinical practice?In the present review, we examine the pitfalls of these published randomized controlled trials, their relevance to present daily clinics, where high-dose external beam RT or brachytherapy is applied, as well as the adoption of ADT in patients with concomitant cardiovascular disorders.

AB - Currently, androgen deprivation therapy (ADT) has a well-defined role when administered together with radiotherapy (RT): neo-adjuvant and concurrent combination for intermediate risk-disease and adjuvant therapy for high risk disease. Evidence of this association was generated by randomized trials designed and led approximately 30 years ago; thus the question which arises is how relevant and portable are these data in our current clinical practice?In the present review, we examine the pitfalls of these published randomized controlled trials, their relevance to present daily clinics, where high-dose external beam RT or brachytherapy is applied, as well as the adoption of ADT in patients with concomitant cardiovascular disorders.

KW - Androgen deprivation therapy

KW - Brachytherapy

KW - Prostate cancer

KW - Radiotherapy

UR - https://www.scopus.com/pages/publications/84927164780

U2 - 10.1016/j.critrevonc.2014.10.003

DO - 10.1016/j.critrevonc.2014.10.003

M3 - Review article

SN - 1040-8428

VL - 93

SP - 136

EP - 148

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

IS - 2

ER -

Combination of androgen deprivation therapy and radiotherapy for localized prostate cancer in the contemporary era

Abstract

OSS delle Nazioni Unite

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo